Nektar Therapeutics provided revenue guidance for the full year 2022. The company announced that GAAP revenue is expected to be between $185 million and $195 million in 2022, including the $100 million of BMS collaboration milestones related to BEMPEG regulatory filings.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.765 USD | +0.86% | +14.67% | +204.42% |
May. 09 | Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q1 Revenue $21.6M, vs. Street Est of $15.3M | MT |
May. 09 | Transcript : Nektar Therapeutics, Q1 2024 Earnings Call, May 09, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+205.31% | 321M | |
+29.90% | 682B | |
+30.35% | 586B | |
-3.72% | 364B | |
+17.55% | 327B | |
+3.49% | 285B | |
+15.53% | 240B | |
+10.16% | 209B | |
-8.14% | 203B | |
+7.33% | 165B |
- Stock Market
- Equities
- NKTR Stock
- News Nektar Therapeutics
- Nektar Therapeutics Provides Revenue Guidance for the Full Year 2022